Consensus Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
8.04 ^USD	-0.99%		-2.55%	-20.08%

Apr. 18	Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024	CI
Apr. 18	Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Executive Vice President, effective May 3, 2024	CI

Evolution of the average Target Price on Vir Biotechnology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f8e8.A3yOIc334BuykavXzZBgxCUz98xOde8gwvijK8a-ook.ZCXrSP2kiVbi1pmGi6kygFcKhfspBocV85rGUfWLxOJGG9QX9L6rTeHUnw~476d9cf8753de7bd7424f0f8e5514120

Analyst Recommendations on Vir Biotechnology, Inc.

HC Wainwright Adjusts Vir Biotechnology Price Target to $110 From $85, Maintains Buy Rating	Feb. 14	MT
JPMorgan Downgrades Vir Biotechnology to Neutral From Overweight, Cuts Price Target to $9 From $23	Jan. 29	MT
BofA Securities Downgrades Vir Biotechnology to Neutral From Buy, Cuts Price Target to $14 From $23 After Shares Underperformance	23-09-08	MT
BofA Securities Downgrades Vir Biotechnology to Neutral From Buy, Adjusts Price Target to $14 From $23	23-09-08	MT
HC Wainwright Adjusts Price Target on Vir Biotechnology to $95 From $100, Keeps Buy Rating	23-08-07	MT
JPMorgan Cuts Vir Biotechnology's Price Target to $24 From $34, Maintains Overweight Rating	23-07-21	MT
Goldman Sachs Adjusts Vir Biotechnology's Price Target to $28 From $51, Keeps Buy Rating	23-07-21	MT
Barclays Adjusts Price Target on Vir Biotechnology to $41 From $59, Maintains Overweight Rating	23-07-21	MT
Morgan Stanley Cuts Vir Biotechnology's Price Target to $15 From $27, Maintains Equalweight Rating	23-07-20	MT
Needham Cuts Vir Biotechnology's Price Target to $22 From $32, Maintains Buy Rating	23-07-20	MT
Morgan Stanley Adjusts Price Target on Vir Biotechnology to $27 From $25, Maintains Equal-Weight Rating	23-04-04	MT
JPMorgan Upgrades Vir Biotechnology to Overweight From Neutral, Adjusts Price Target to $34 From $35	23-03-06	MT
HC Wainwright Adjusts Price Target on Vir Biotechnology to $100 From $125, Keeps Buy Rating	23-03-06	MT
Goldman Sachs Upgrades Vir Biotechnology to Buy From Neutral, Adjusts Price Target to $53 From $41	23-02-21	MT
Morgan Stanley Upgrades Vir Biotechnology to Equal Weight From Underweight, Adjusts Price Target to $30 From $18	23-01-27	MT
SVB Securities Adjusts Vir Biotechnology's Price Target to $43 From $45, Maintains Outperform Rating	23-01-27	MT
Needham Adjusts Price Target on Vir Biotechnology to $32 From $35, Maintains Buy Rating	22-11-04	MT
SVB Securities Starts Vir Biotechnology at Outperform With $40 Price Target	22-09-14	MT
Morgan Stanley Initiates Vir Biotechnology at Underweight With $15 Price Target	22-09-09	MT
HC Wainwright Adjusts Vir Biotechnology Price Target to $125 From $200, Maintains Buy Rating	22-05-12	MT
HC Wainwright Adjusts Vir Biotechnology's Price Target to $200 From $300, Reiterates Buy Rating	22-03-30	MT
Needham Adjusts Vir Biotechnology's Price Target to $45 from $80, Keeps Buy Rating	22-03-28	MT
Baird Upgrades Vir Biotechnology to Neutral From Underperform, Adjusts Price Target to $28 From $36	22-03-03	MT
HC Wainwright Adjusts Vir Biotechnology's Price Target to $300 from $200, Keeps Buy Rating	21-12-21	MT
Baird Downgrades Vir Biotechnology to Underperform From Neutral; Price Target is $36	21-12-21	MT